Saturday, October 24, 2015 Cincinnati, Ohio
Accreditation


Overview of the 14th Annual Psychopharmacology Update


This well-established one-day CME symposium offers an outstanding opportunity for education and networking with minimal disruption to your busy schedule. At this full-day course, nationally renowned faculty will cover psychopharmacology of special populations. You will get in-depth analysis from our expert faculty and ample time to query them on topics that will help keep your practice ahead of the curve.

Who Should Attend
The 2015 Psychopharmacology Update is a CME conference designed for child and adolescent psychiatrists, general psychiatrists, geriatric psychiatrists, nurse practitioners, physician assistants, nurses, psychologists, social workers, and other mental health professionals interested in treating patients with psychiatric disorders to remission with measurement based care


Continuing Medical Education


Physician Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Global Academy for Medical Education, Inc. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
The University of Cincinnati designates this Live Activity for a maximum of 7.5 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants Credit Designation
The American Academy of Physician Assistants (AAPA) accepts Category 1 CME approval from organizations accredited by the ACCME to grant Category 1 hours toward the PRA.

Nurse Practitioners
The American Association of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit(s) from organizations accredited by the ACCME.


Learning Objectives


At the conclusion of this activity, participants should be able to:

  • Implement rational pharmacological strategies to manage acute and persistent aggressive behavior in persons with schizophrenia.
  • Identify evidenced-based treatments for posttraumatic stress disorder
  • Discuss the risk/benefit considerations in medication prescribing among women of reproductive potential and specifically during pregnancy.
  • Discuss the course of mood disorders across pregnancy and postpartum
  • Describe the current evidence for selective serotonin reuptake inhibitors (SSRIs) and selective serotonin norepinephrine reuptake inhibitors (SNRIs) in youth with anxiety and depressive disorders and will become familiar with "next step" interventions following initial psychopharmacologic approaches to the pediatric patient with major depressive disorder